- Home
- ARMP vs CUE Comparison
ARMP vs CUE Comparison
Compare ARMP & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- CUE
- Stock Information
- Founded
- ARMP N/A
- CUE 2014
- Country
- ARMP United States
- CUE United States
- Employees
- ARMP N/A
- CUE N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- ARMP Health Care
- CUE Health Care
- Exchange
- ARMP Nasdaq
- CUE Nasdaq
- Market Cap
- ARMP 52.1M
- CUE 57.7M
- IPO Year
- ARMP N/A
- CUE 2018
- Fundamental
- Price
- ARMP $2.54
- CUE $0.74
- Analyst Decision
- ARMP Strong Buy
- CUE Strong Buy
- Analyst Count
- ARMP 1
- CUE 3
- Target Price
- ARMP $9.00
- CUE $3.00
- AVG Volume (30 Days)
- ARMP 13.2K
- CUE 520.8K
- Earning Date
- ARMP 08-12-2025
- CUE 08-13-2025
- Dividend Yield
- ARMP N/A
- CUE N/A
- EPS Growth
- ARMP N/A
- CUE N/A
- EPS
- ARMP N/A
- CUE N/A
- Revenue
- ARMP $4,699,000.00
- CUE $7,991,000.00
- Revenue This Year
- ARMP $8.43
- CUE N/A
- Revenue Next Year
- ARMP N/A
- CUE $23.84
- P/E Ratio
- ARMP N/A
- CUE N/A
- Revenue Growth
- ARMP 14.24
- CUE 13.83
- 52 Week Low
- ARMP $0.90
- CUE $0.45
- 52 Week High
- ARMP $2.96
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- ARMP 65.04
- CUE 43.63
- Support Level
- ARMP $2.14
- CUE $0.84
- Resistance Level
- ARMP $2.61
- CUE $0.90
- Average True Range (ATR)
- ARMP 0.14
- CUE 0.10
- MACD
- ARMP -0.00
- CUE -0.02
- Stochastic Oscillator
- ARMP 81.08
- CUE 11.27
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.